| P50 | author | Mariona Cabo | Q59548556 |
| | Federico Rojo | Q61766016 |
| | Miguel López-Botet | Q46153132 |
| | Aura Muntasell | Q46153170 |
| P2093 | author name string | Ana Rovira | |
| | Joan Albanell | |
| | Ignasi Tusquets | |
| | Sonia Servitja | |
| | María Martínez-García | |
| P2860 | cites work | CD56(dim)CD16(+) NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases | Q79656747 |
| | Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy | Q81038993 |
| | Trastuzumab in the treatment of breast cancer | Q81374982 |
| | Identification of the NKG2D haplotypes associated with natural cytotoxic activity of peripheral blood lymphocytes and cancer immunosurveillance | Q82193347 |
| | HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients | Q82347187 |
| | Lapatinib enhances herceptin-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression | Q84830887 |
| | Metastatic consequences of immune escape from NK cell cytotoxicity by human breast cancer stem cells | Q87674205 |
| | Interplay between the levels of estrogen and estrogen receptor controls the level of the granzyme inhibitor, proteinase inhibitor 9 and susceptibility to immune surveillance by natural killer cells | Q24293644 |
| | Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule | Q24314704 |
| | Tumor-associated MICA is shed by ADAM proteases | Q24320055 |
| | Exploiting a natural conformational switch to engineer an interleukin-2 'superkine' | Q24632192 |
| | The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity | Q24651041 |
| | Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells | Q24675226 |
| | Killer cell lectin-like receptor G1 binds three members of the classical cadherin family to inhibit NK cell cytotoxicity | Q24676938 |
| | Tumour Fas ligand:Fas ratio greater than 1 is an independent marker of relative resistance to tamoxifen therapy in hormone receptor positive breast cancer | Q24801183 |
| | NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy? | Q26746478 |
| | Newtonian cell interactions shape natural killer cell education | Q26797240 |
| | Adaptive Immune Resistance: How Cancer Protects from Immune Attack | Q26798448 |
| | Interleukin 12: still a promising candidate for tumor immunotherapy? | Q26861559 |
| | Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy | Q27004011 |
| | NK cells in the tumor microenvironment | Q27692606 |
| | Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial | Q27851705 |
| | Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831 | Q27853035 |
| | Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 |
| | NKG2D Ligands in Tumor Immunity: Two Sides of a Coin | Q28083832 |
| | The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy | Q28088784 |
| | Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets | Q28140238 |
| | Proteinase inhibitor 9, an inhibitor of granzyme B-mediated apoptosis, is a primary estrogen-inducible gene in human liver cells | Q28145125 |
| | MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer | Q28198153 |
| | KIR: diverse, rapidly evolving receptors of innate and adaptive immunity | Q28203441 |
| | Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy | Q28235277 |
| | Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial | Q28254919 |
| | H-2RIIBP, a member of the nuclear hormone receptor superfamily that binds to both the regulatory element of major histocompatibility class I genes and the estrogen response element | Q28508930 |
| | The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions | Q28589215 |
| | Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands | Q28972540 |
| | Fcgamma receptors as regulators of immune responses | Q29615584 |
| | Up on the tightrope: natural killer cell activation and inhibition | Q29619175 |
| | The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans | Q33292180 |
| | Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells | Q33292289 |
| | Stromal gene expression predicts clinical outcome in breast cancer | Q33330931 |
| | Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer | Q33418729 |
| | Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial | Q33441996 |
| | Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to PreoperativeTrastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer | Q33712476 |
| | Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study | Q33739253 |
| | HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy | Q33785744 |
| | Targeting CD137 enhances the efficacy of cetuximab. | Q33872482 |
| | Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population | Q33928216 |
| | The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity | Q34073138 |
| | Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells | Q34149109 |
| | Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. | Q34178128 |
| | Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer | Q34270064 |
| | Dendritic cell editing by activated natural killer cells results in a more protective cancer-specific immune response | Q34314259 |
| | ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer | Q34334333 |
| | PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma | Q37687323 |
| | IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM). | Q37709365 |
| | Protecting a serial killer: pathways for perforin trafficking and self-defence ensure sequential target cell death | Q38011488 |
| | Combination strategies to enhance antitumor ADCC. | Q38014085 |
| | Activating natural cytotoxicity receptors of natural killer cells in cancer and infection | Q38082002 |
| | Molecular determinants of trastuzumab efficacy: What is their clinical relevance? | Q38096651 |
| | Cancer immunosurveillance and immunoediting by natural killer cells | Q38165687 |
| | The DNA Damage Response: A Common Pathway in the Regulation of NKG2D and DNAM-1 Ligand Expression in Normal, Infected, and Cancer Cells. | Q38178966 |
| | The immune system and response to HER2-targeted treatment in breast cancer | Q38183569 |
| | Human NK cell response to pathogens | Q38192286 |
| | Effect of tumor cells and tumor microenvironment on NK-cell function. | Q38207947 |
| | Upmodulation by estrogen of HLA class I expression in breast tumor cell lines | Q38312412 |
| | CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells | Q38323397 |
| | Nectins and nectin-like molecules in development and disease | Q38367019 |
| | Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial. | Q38385131 |
| | NK Cells and Cancer Immunoediting | Q38508211 |
| | Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions. | Q38542034 |
| | Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions | Q38542213 |
| | Human KIR repertoires: shaped by genetic diversity and evolution | Q38568881 |
| | Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS. | Q38576510 |
| | Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells. | Q38619194 |
| | Clinical relevance of host immunity in breast cancer: from TILs to the clinic | Q38669465 |
| | Antibody-Dependent NK Cell Activation Differentially Targets EBV-Infected Cells in Lytic Cycle and Bystander B Lymphocytes Bound to Viral Antigen-Containing Particles | Q38718440 |
| | Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells | Q38805640 |
| | Targeting natural killer cells in cancer immunotherapy | Q38829849 |
| | NK Cell and Ig Interplay in Defense against Herpes Simplex Virus Type 1: Epistatic Interaction of CD16A and IgG1 Allotypes of Variable Affinities Modulates Antibody-Dependent Cellular Cytotoxicity and Susceptibility to Clinical Reactivation. | Q38852424 |
| | Antibody-mediated response of NKG2Cbright NK cells against human cytomegalovirus. | Q38911174 |
| | The genomic landscape of breast cancer and its interaction with host immunity | Q38915694 |
| | Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy | Q38952555 |
| | Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30. | Q39000284 |
| | PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients | Q39036924 |
| | Targeting NK-cell checkpoints for cancer immunotherapy | Q39150423 |
| | Dual Role of Natural Killer Cells on Graft Rejection and Control of Cytomegalovirus Infection in Renal Transplantation. | Q39162642 |
| | Type I Interferons and Natural Killer Cell Regulation in Cancer | Q39241784 |
| | Activation, coactivation, and costimulation of resting human natural killer cells | Q36652166 |
| | Taking license with natural killer cell maturation and repertoire development | Q36652192 |
| | IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production | Q36671364 |
| | Correlation between NK function and response to trastuzumab in metastatic breast cancer patients | Q36702442 |
| | Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition. | Q36729376 |
| | Antibodies, Fc receptors and cancer | Q36732841 |
| | Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies | Q36787500 |
| | Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients | Q36806268 |
| | NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). | Q36814614 |
| | Trastuzumab upregulates expression of HLA-ABC and T cell costimulatory molecules through engagement of natural killer cells and stimulation of IFNγ secretion. | Q36821168 |
| | Epirubicin pretreatment enhances NK cell-mediated cytotoxicity against breast cancer cells in vitro | Q36841139 |
| | Immune-refractory cancers and their little helpers--an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E? | Q36927830 |
| | IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas | Q37085973 |
| | Comprehensive molecular profiling of the B7 family of immune-regulatory ligands in breast cancer. | Q37224577 |
| | Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients | Q37292031 |
| | KIR Genes and Their Ligands Predict the Response to Anti-EGFR Monoclonal Antibodies in Solid Tumors. | Q37471733 |
| | Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions. | Q48263702 |
| | Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. | Q50908445 |
| | PolyI:C and CpG Synergize with Anti-ErbB2 mAb for Treatment of Breast Tumors Resistant to Immune Checkpoint Inhibitors. | Q51053344 |
| | First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. | Q51170722 |
| | E-cadherin expression in estrogen receptor-positive and negative breast carcinomas of postmenopausal women. | Q53333139 |
| | Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer | Q54631094 |
| | Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer. | Q55041652 |
| | Imprint of human cytomegalovirus infection on the NK cell receptor repertoire | Q56169020 |
| | Soluble MICA in malignant diseases | Q57257239 |
| | Elements Related to Heterogeneity of Antibody-Dependent Cell Cytotoxicity in Patients Under Trastuzumab Therapy for Primary Operable Breast Cancer Overexpressing Her2 | Q62604205 |
| | Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2 | Q62604209 |
| | A HLA class I cis-regulatory element whose activity can be modulated by hormones | Q72804306 |
| | Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors | Q73400031 |
| | Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity | Q78469598 |
| | Regulation of perforin‐independent NK cell‐mediated cytotoxicity | Q79092479 |
| | HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines | Q39402352 |
| | Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition | Q39470152 |
| | Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models | Q39519148 |
| | Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors | Q39546314 |
| | E-cadherin expression on human carcinoma cell affects trastuzumab-mediated antibody-dependent cellular cytotoxicity through killer cell lectin-like receptor G1 on natural killer cells | Q39579131 |
| | NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs | Q39624540 |
| | Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma | Q39679967 |
| | The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody | Q39705098 |
| | CIS is a potent checkpoint in NK cell-mediated tumor immunity | Q39744193 |
| | Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models | Q39771295 |
| | Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity | Q39908130 |
| | Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. | Q40001571 |
| | Control of Metastasis by NK Cells | Q40092674 |
| | Human NK cell education by inhibitory receptors for MHC class I. | Q40244934 |
| | Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells | Q40333010 |
| | Adaptive NKG2C+ NK Cell Response and the Risk of Cytomegalovirus Infection in Kidney Transplant Recipients. | Q40425776 |
| | DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction | Q40446320 |
| | Paclitaxel probably enhances cytotoxicity of natural killer cells against breast carcinoma cells by increasing perforin production. | Q40481593 |
| | A comparison of the in vitro and in vivo activities of IgG and F(ab')2 fragments of a mixture of three monoclonal anti-Her-2 antibodies | Q40552147 |
| | Trastuzumab (Herceptin) enhances class I-restricted antigen presentation recognized by HER-2/neu-specific T cytotoxic lymphocytes | Q40568569 |
| | Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. | Q40616262 |
| | Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization | Q40627446 |
| | Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain | Q40745788 |
| | TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway | Q40788629 |
| | STAT5 Is a Key Regulator in NK Cells and Acts as a Molecular Switch from Tumor Surveillance to Tumor Promotion | Q40912349 |
| | Cell-Extrinsic MHC Class I Molecule Engagement Augments Human NK Cell Education Programmed by Cell-Intrinsic MHC Class I. | Q40967373 |
| | Clinical significance of novel costimulatory molecule B7-H6 in human breast cancer | Q41144481 |
| | Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab | Q41344399 |
| | Serial killing of tumor cells by human natural killer cells--enhancement by therapeutic antibodies | Q41858652 |
| | IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function | Q42134875 |
| | Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy | Q42182888 |
| | Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker | Q42221543 |
| | NKG2C zygosity influences CD94/NKG2C receptor function and the NK-cell compartment redistribution in response to human cytomegalovirus | Q42270076 |
| | A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma | Q42609665 |
| | VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. | Q42723314 |
| | HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway. | Q42832247 |
| | ADAM10 and ADAM17: New players in trastuzumab tesistance. | Q43106106 |
| | Natural Killer (NK)/melanoma cell interaction induces NK-mediated release of chemotactic High Mobility Group Box-1 (HMGB1) capable of amplifying NK cell recruitment. | Q43185293 |
| | Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function | Q43442797 |
| | Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells | Q43760313 |
| | Classification of human natural killer cells based on migration behavior and cytotoxic response. | Q44652404 |
| | Cellular immunity in breast cancer patients completing taxane treatment | Q44909385 |
| | Peripheral blood NK cells from breast cancer patients are tumor-induced composite subsets. | Q45344093 |
| | HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice | Q45736903 |
| | Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. | Q46108181 |
| | Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study. | Q47766707 |
| | Regulation of interferon-gamma production by IL-12 and IL-18. | Q47933801 |
| | A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies | Q34376968 |
| | A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab | Q34382125 |
| | Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype | Q34434169 |
| | The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis | Q34493341 |
| | Recognition of tumors by the innate immune system and natural killer cells | Q34496462 |
| | Natural killer cell memory in infection, inflammation and cancer | Q34510646 |
| | Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells | Q34672927 |
| | Targeting the function of the HER2 oncogene in human cancer therapeutics | Q34766486 |
| | IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells | Q34798580 |
| | Natural killer cells and dendritic cells: rendezvous in abused tissues | Q35014074 |
| | Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. | Q35102480 |
| | HMGB1-promoted and TLR2/4-dependent NK cell maturation and activation take part in rotavirus-induced murine biliary atresia | Q35126397 |
| | The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer? | Q35206311 |
| | Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity | Q35208414 |
| | Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. | Q35437978 |
| | Unravelling natural killer cell function: triggering and inhibitory human NK receptors | Q35611389 |
| | Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect | Q35639002 |
| | The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. | Q35740186 |
| | Prognostic and predictive value of PDL1 expression in breast cancer | Q35741710 |
| | Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer | Q35780315 |
| | Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy | Q35789363 |
| | Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer | Q35807188 |
| | Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties | Q35889630 |
| | Mechanisms of resistance to TRAIL-induced apoptosis in cancer | Q35954258 |
| | MHC class I molecules and KIRs in human history, health and survival | Q36047157 |
| | Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications | Q36088788 |
| | Progressive loss of anti-HER2 CD4(+) T-helper type 1 response in breast tumorigenesis and the potential for immune restoration | Q36107949 |
| | Cancer immunoediting by the innate immune system in the absence of adaptive immunity. | Q36278057 |
| | Resistance to Trastuzumab in Breast Cancer. | Q36318226 |
| | Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression | Q36388523 |
| | Antitumor antibodies in the treatment of cancer: Fc receptors link opsonic antibody with cellular immunity | Q36500807 |
| | CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT. | Q36540532 |
| | A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer | Q36547750 |
| | Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? | Q36613598 |
| | Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes | Q36624237 |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 1544 | |
| P577 | publication date | 2017-11-13 | |
| P1433 | published in | Frontiers in Immunology | Q27723748 |
| P1476 | title | Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy | |
| P478 | volume | 8 | |